Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin with High-Dose Chemotherapy and ASCT for Multiple Myeloma
NCT01207765Phase 2Terminated
- Sponsor
- Tufts Medical Center
- Start
- Apr 2008
- Primary completion
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in multiple myeloma (MM), sponsored by Tufts Medical Center. Primary endpoint: Safety and Efficacy. Started Apr 2008; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01207765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01207765.